Targeting the PI3K Pathway in HR+/HER2- MBC

Download this slideset to review the latest clinical data on the evolving role of mTOR, PIK3, and ALK inhibitors in the treatment of HR+/HER2- metastatic breast cancer.
Sara Hurvitz, MD, FACP
Format: Microsoft PowerPoint (.ppt)
File Size: 1.05 MB
Released: May 31, 2019


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation

For further information concerning Lilly grant funding, visit

Related Content

CCO faculty Sara Hurvitz, MD, FACP, provides her thoughts on key studies in HER2+ breast cancer presented at the 2019 Breast Cancer meeting in San Antonio

Sara Hurvitz, MD, FACP Released: January 13, 2020

Results from PEARL study of palbociclib with endocrine therapy in patients with HR+/HER- MBC and disease progression on prior AI therapy from SABCS 2019 as reported by Clinical Care Options (CCO)

Released: December 20, 2019

Second interim OS analysis of SOPHIA trial of margetuximab + CT vs trastuzumab + CT for previously treated HER2+ MBC from SABCS 2019 as reported by Clinical Care Options

Released: December 20, 2019

Results from plasmaMATCH trial using ctDNA testing to guide targeted therapy selection for patients with advanced breast cancer from SABCS 2019 as reported by Clinical Care Options (CCO)

Released: December 20, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?